Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches01:23

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...
Clinical Trials01:16

Clinical Trials

Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
Pharmacovigilance01:19

Pharmacovigilance

Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
Hazard Ratio01:12

Hazard Ratio

The hazard ratio (HR) is a widely used measure in clinical trials to compare the risk of events, such as death or disease recurrence, between two groups over time. It reflects the ratio of hazard rates—the instantaneous risk of the event occurring—between a treatment group and a control group. This measure provides valuable insights into the relative effectiveness of a treatment by assessing how the risk of an event differs between the two groups.
For example, in a clinical trial evaluating a...
Clinical Trials: Overview01:11

Clinical Trials: Overview

Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
Genetic Screens02:46

Genetic Screens

Genetic screens are tools used to identify genes and mutations responsible for phenotypes of interest. Genetic screens help identify individuals or a group of people at risk of developing  genetic diseases and help them with early intervention, targeted therapy, and reproductive options.
Forward genetic screens
Forward or “classical” genetic screens involve creating random mutations in an organism’s DNA using radiation, mutagens, or insertion of additional bases, which result in visible changes...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A framework for assessing the impact of accelerated approval.

PloS one·2022
Same author

Bayesian screening for feature selection.

Journal of biopharmaceutical statistics·2022
Same author

BMA-Mod: A Bayesian model averaging strategy for determining dose-response relationships in the presence of model uncertainty.

Biometrical journal. Biometrische Zeitschrift·2018
Same author

Principled Structured Incorporation of Clinical Knowledge Into Strategic Development Decisions.

Therapeutic innovation & regulatory science·2018
Same author

Methods and Issues to Consider for Detection of Safety Signals From Spontaneous Reporting Databases: A Report of the DIA Bayesian Safety Signal Detection Working Group.

Therapeutic innovation & regulatory science·2018
Same author

Unified screening for potential elevated adverse event risk and other associations.

Statistics in medicine·2018
Same journal

Comparison of Different Methods for the Meta-Analysis of Diagnostic Test Accuracy Studies-A Simulation Study.

Biometrical journal. Biometrische Zeitschrift·2026
Same journal

When to Adjust for Multiple Testing: A Unifying Guiding Principle.

Biometrical journal. Biometrische Zeitschrift·2026
Same journal

Ensuring Quality in Preclinical Research: The Importance of Being Human.

Biometrical journal. Biometrische Zeitschrift·2026
Same journal

Addressing Cluster-Level Treatment Effect Heterogeneity in Sample Size Determination for Hierarchical 2 × 2 Factorial Designs.

Biometrical journal. Biometrische Zeitschrift·2026
Same journal

A Multiple Imputation Approach to Distinguish Curative From Life-Prolonging Effects in the Presence of Missing Covariates.

Biometrical journal. Biometrische Zeitschrift·2026
Same journal

Tests for Categorical Data Beyond Pearson: A Distance Covariance and Energy Distance Approach.

Biometrical journal. Biometrische Zeitschrift·2026
See all related articles

Related Experiment Video

Updated: Jun 28, 2026

Implementation of a Real-Time Psychosis Risk Detection and Alerting System Based on Electronic Health Records using CogStack
07:31

Implementation of a Real-Time Psychosis Risk Detection and Alerting System Based on Electronic Health Records using CogStack

Published on: May 15, 2020

Detecting potential safety issues in clinical trials by Bayesian screening.

A Lawrence Gould1

  • 1Merck Research Laboratories, UG1D-88, 351 North Sumneytown Pike, North Wales, PA 19454, USA. larry_gould@merck.com

Biometrical Journal. Biometrische Zeitschrift
|October 22, 2008
PubMed
Summary
This summary is machine-generated.

This study introduces a Bayesian screening method for analyzing adverse events in clinical trials. It offers a more reliable way to assess drug-event associations and manage multiplicity issues compared to traditional testing.

More Related Videos

A Machine Learning Approach to Design an Efficient Selective Screening of Mild Cognitive Impairment
12:18

A Machine Learning Approach to Design an Efficient Selective Screening of Mild Cognitive Impairment

Published on: January 11, 2020

Related Experiment Videos

Last Updated: Jun 28, 2026

Implementation of a Real-Time Psychosis Risk Detection and Alerting System Based on Electronic Health Records using CogStack
07:31

Implementation of a Real-Time Psychosis Risk Detection and Alerting System Based on Electronic Health Records using CogStack

Published on: May 15, 2020

A Machine Learning Approach to Design an Efficient Selective Screening of Mild Cognitive Impairment
12:18

A Machine Learning Approach to Design an Efficient Selective Screening of Mild Cognitive Impairment

Published on: January 11, 2020

Area of Science:

  • Clinical Trials
  • Biostatistics
  • Pharmacovigilance

Background:

  • Large clinical trials often reveal numerous unanticipated adverse events.
  • Traditional hypothesis testing for adverse events presents challenges, including issues with multiplicity and interpretation of non-significant findings.

Purpose of the Study:

  • To present a novel Bayesian screening approach for analyzing adverse events in clinical trials.
  • To offer a method that self-adjusts for multiplicity and directly assesses the likelihood of drug-event association.

Main Methods:

  • A Bayesian screening approach is described, which avoids hypothesis testing.
  • The method incorporates investigator-defined criteria for treatment-association and quantifies association strength.
  • Diagnostic properties are evaluated analytically.

Main Results:

  • The Bayesian screening approach provides a direct assessment of the likelihood of no material drug-event association.
  • The method quantifies the strength of observed associations and is self-adjusting for multiplicity.
  • Application to a vaccine trial yielded results comparable to false discovery rate and hierarchical Bayes methods.

Conclusions:

  • The Bayesian screening approach offers a robust alternative to conventional hypothesis testing for adverse events in clinical trials.
  • This method enhances the assessment of drug-event relationships by incorporating clinical judgment and providing clear probabilistic interpretations.
  • The approach is suitable for managing multiplicity and evaluating potential risks in large-scale studies.